Get the Stockscreener App
5.63
1.05%
-0.06
Pre-market:
5.52
-0.11
-1.95%
Fennec Pharmaceuticals Inc stock is traded at $5.63, with a volume of 22,746.
It is down -1.05% in the last 24 hours and down -12.44% over the past month.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
See More
Previous Close:
$5.69
Open:
$5.69
24h Volume:
22,746
Relative Volume:
0.29
Market Cap:
$143.76M
Revenue:
$21.25M
Net Income/Loss:
$-16.05M
P/E Ratio:
-9.2295
EPS:
-0.61
Net Cash Flow:
$-17.14M
1W Performance:
+10.83%
1M Performance:
-12.44%
6M Performance:
+32.78%
1Y Performance:
-38.54%
1-Day Range:
$5.54
$5.745
1-Week Range:
$5.02
$5.75
52-Week Range:
$3.96
$10.07
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Name
Fennec Pharmaceuticals Inc
Sector
Industry
Phone
(919) 636-4530
Address
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
5.63 | 143.76M | 21.25M | -16.05M | -17.14M | -0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Aug-08-22 | Resumed | Craig Hallum | Buy |
| Jun-05-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-11-18 | Initiated | Goldman | Buy |
Fennec Pharmaceuticals Inc Stock (FENC) Latest News
Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price Is Matching Sentiment Around Its Revenues - simplywall.st
Where are the Opportunities in (FENC) - news.stocktradersdaily.com
Fennec Pharmaceuticals: Top 10 Undervalued Biotechnology Industry Stocks (FRX) - The Globe and Mail
(FRX) Market Insights and Trading Signals (FRX:CA) - news.stocktradersdaily.com
(FRX) Advanced Trading Insights (FRX:CA) - news.stocktradersdaily.com
Norgine introduces PEDMARQSI in Germany for pediatric cancer care - MSN
(FENC) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Breakeven Is Near for Fennec Pharmaceuticals Inc. (NASDAQ:FENC) - Yahoo
Fennec Pharmaceuticals director Raykov Rosty sells $52,500 in shares By Investing.com - Investing.com South Africa
Fennec Pharmaceuticals director Raykov Rosty sells $52,500 in shares - Investing.com
Vitro Diagnostics (OTCMKTS:VODG) & Fennec Pharmaceuticals (NASDAQ:FENC) Head to Head Survey - Defense World
Fennec Pharmaceuticals (TSE:FRX) Share Price Passes Below 50 Day Moving Average – Should You Sell? - Defense World
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
(FENC) Investment Analysis and Advice - news.stocktradersdaily.com
Fennec Pharmaceuticals Achieves Strong Growth and Expands Market Reach in 2024 - TipRanks
Long Term Trading Analysis for (FRX) (FRX:CA) - news.stocktradersdaily.com
(FRX) Stock Market Analysis (FRX:CA) - news.stocktradersdaily.com
(FENC) Technical Data - news.stocktradersdaily.com
(FRX) Equity Market Report (FRX:CA) - news.stocktradersdaily.com
Q1 EPS Forecast for Fennec Pharmaceuticals Raised by Analyst - Defense World
HC Wainwright Has Positive Forecast for TSE:FRX Q1 Earnings - Defense World
Wedbush Research Analysts Boost Earnings Estimates for FENC - Defense World
What is HC Wainwright’s Forecast for FENC Q1 Earnings? - Defense World
US$12.60: That's What Analysts Think Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Is Worth After Its Latest Results - Simply Wall St
Wedbush Boosts Earnings Estimates for Fennec Pharmaceuticals - Defense World
Fennec Pharmaceuticals (FENC) Projected to Post Quarterly Earnings on Thursday - Defense World
Fennec Pharmaceuticals: Strong Growth Potential with PEDMARK’s Market Expansion and Strategic Focus - TipRanks
Fennec Pharmaceuticals (NASDAQ:FENC) Receives Buy Rating from HC Wainwright - Defense World
Fennec Pharmaceuticals Reports Strong Growth Amid Challenges - TipRanks
Fennec Pharmaceuticals: Strategic Market Expansion and Financial Performance Justify Buy Rating - TipRanks
(FRX) Technical Data (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2024 Earnings Call Transcript - Insider Monkey
Rhumbline Advisers Grows Holdings in Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
Fennec Pharmaceuticals Reports Strong 2024 Sales Growth - TipRanks
Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results - TradingView
Earnings call transcript: Fennec Pharmaceuticals Q4 2024 earnings beat forecasts By Investing.com - Investing.com South Africa
Wedbush Reviews Fennec Pharmaceuticals' Q4 -March 10, 2025 at 12:48 pm EDT - Marketscreener.com
Fennec Pharmaceuticals Q4 revenue beats, stock tumbles 16% By Investing.com - Investing.com Canada
Fennec Pharmaceuticals Q4 revenue beats, stock tumbles 16% - Investing.com
Fennec Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Fennec Pharmaceuticals Q4 2024 earnings beat forecasts - Investing.com
Investing in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago would have delivered you a 38% gain - Yahoo Finance
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Fennec Pharmaceuticals Reports Strong 2024 Financials and Expands Global Reach - TipRanks
Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - The Manila Times
FENNEC PHARMACEUTICALS Earnings Results: $FENC Reports Quarterly Earnings - Nasdaq
Earnings Flash (FRX.TO) Fennec Pharmaceuticals Posts Q4 Revenue US$7.925 Million - Marketscreener.com
Fennec Pharmaceuticals Inc Q4 Loss Decreases, Beats Estimates - Nasdaq
Earnings Scheduled For March 10, 2025 - Benzinga
Fennec Pharmaceuticals (FENC) Projected to Post Quarterly Earnings on Monday - Defense World
Fennec Pharmaceuticals director Raykov sells $67,900 in stock By Investing.com - Investing.com Canada
Fennec Pharmaceuticals Inc Stock (FENC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):